Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Aaron Joel Goldman, Ph.D.

Title
Institution
Department
Address
Phone
Fax
Profile Picture

Overview

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Goldman A, Smalley JL, Mistry M, Krenzlin H, Zhang H, Dhawan A, Caldarone B, Moss SJ, Silbersweig DA, Lawler SE, Braun IM. A computationally inspired in-vivo approach identifies a link between amygdalar transcriptional heterogeneity, socialization and anxiety. Transl Psychiatry. 2019 12 09; 9(1):336. PMID: 31819040.
    Citations:    
  2. Craig M, Kaveh K, Woosley A, Brown AS, Goldman D, Eton E, Mehta RM, Dhawan A, Arai K, Rahman MM, Chen S, Nowak MA, Goldman A. Cooperative adaptation to therapy (CAT) confers resistance in heterogeneous non-small cell lung cancer. PLoS Comput Biol. 2019 08; 15(8):e1007278. PMID: 31449515.
    Citations:    
  3. Goldman A, Khiste S, Freinkman E, Dhawan A, Majumder B, Mondal J, Pinkerton AB, Eton E, Medhi R, Chandrasekar V, Rahman MM, Ichimura T, Gopinath KS, Majumder P, Kohandel M, Sengupta S. Targeting tumor phenotypic plasticity and metabolic remodeling in adaptive cross-drug tolerance. Sci Signal. 2019 08 20; 12(595). PMID: 31431543.
    Citations:    
  4. Raza M, Prasad P, Gupta P, Kumar N, Sharma T, Rana M, Goldman A, Sehrawat S. Perspectives on the role of brain cellular players in cancer-associated brain metastasis: translational approach to understand molecular mechanism of tumor progression. Cancer Metastasis Rev. 2018 12; 37(4):791-804. PMID: 30284650.
    Citations:    Fields:    
  5. Goldman A. Drug-induced resistance: nipping it in the 'budding'. Oncotarget. 2018 Nov 13; 9(89):35873-35874. PMID: 30543207.
    Citations:    
  6. Jash E, Prasad P, Kumar N, Sharma T, Goldman A, Sehrawat S. Perspective on nanochannels as cellular mediators in different disease conditions. Cell Commun Signal. 2018 11 08; 16(1):76. PMID: 30409198.
    Citations:    Fields:    
  7. Kaushansky A, Hedstrom L, Goldman A, Singh J, Yang PL, Rathod PK, Cynamon M, Wodarz D, Mahadevan D, Tomaras A, Navia MA, Schiffer CA. A call to arms: Unifying the fight against resistance. Sci Signal. 2018 10 23; 11(553). PMID: 30352947.
    Citations:    Fields:    
  8. Kumar N, Prasad P, Jash E, Jayasundar S, Singh I, Alam N, Murmu N, Somashekhar SP, Goldman A, Sehrawat S. cAMP regulated EPAC1 supports microvascular density, angiogenic and metastatic properties in a model of triple negative breast cancer. Carcinogenesis. 2018 10 08; 39(10):1245-1253. PMID: 29982410.
    Citations:    Fields:    
  9. Kumar N, Prasad P, Jash E, Saini M, Husain A, Goldman A, Sehrawat S. Insights into exchange factor directly activated by cAMP (EPAC) as potential target for cancer treatment. Mol Cell Biochem. 2018 Oct; 447(1-2):77-92. PMID: 29417338.
    Citations:    Fields:    Translation:HumansAnimalsCells
  10. Maciejko L, Smalley M, Goldman A. . Cancer Immunotherapy and Personalized Medicine: Emerging Technologies and Biomarker-Based Approaches. J. Mol. Bio. & Diag. 2017.
  11. Dhandapani M, Goldman A. Preclinical Cancer Models and Biomarkers for Drug Development: New Technologies and Emerging Tools. J. Mol. Bio. & Diag. In Press. 2017.
  12. Goldman A, Kohandel M, Clairambault J. Integrating Biological and Mathematical Models to Explain and Overcome Drug Resistance in Cancer, Part 1: Biological Facts and Studies in Drug Resistance. Current Stem Cell Reports. In Press. 2017.
  13. Dhandapani M, Goldman A. Preclinical Cancer Models and Biomarkers for Drug Development: New Technologies and Emerging Tools. J Mol Biomark Diagn. 2017 Sep; 8(5). PMID: 29285415.
    Citations:    
  14. Maciejko L, Smalley M, Goldman A. Cancer Immunotherapy and Personalized Medicine: Emerging Technologies and Biomarker-Based Approaches. J Mol Biomark Diagn. 2017 Sep; 8(5). PMID: 29285416.
    Citations:    
  15. Calibasi Kocal G, Güven S, Foygel K, Goldman A, Chen P, Sengupta S, Paulmurugan R, Baskin Y, Demirci U. Dynamic Microenvironment Induces Phenotypic Plasticity of Esophageal Cancer Cells Under Flow. Sci Rep. 2016 12 02; 6:38221. PMID: 27910892.
    Citations: 2     Fields:    Translation:HumansCells
  16. Kulkarni A, Pandey P, Rao P, Mahmoud A, Goldman A, Sabbisetti V, Parcha S, Natarajan SK, Chandrasekar V, Dinulescu D, Roy S, Sengupta S. Algorithm for Designing Nanoscale Supramolecular Therapeutics with Increased Anticancer Efficacy. ACS Nano. 2016 09 27; 10(9):8154-68. PMID: 27452234.
    Citations: 1     Fields:    Translation:Cells
  17. Goldman A, Kulkarni A, Kohandel M, Pandey P, Rao P, Natarajan SK, Sabbisetti V, Sengupta S. Rationally Designed 2-in-1 Nanoparticles Can Overcome Adaptive Resistance in Cancer. ACS Nano. 2016 06 28; 10(6):5823-34. PMID: 27257911.
    Citations: 5     Fields:    
  18. Molavian HR, Goldman A, Phipps CJ, Kohandel M, Wouters BG, Sengupta S, Sivaloganathan S. Drug-induced reactive oxygen species (ROS) rely on cell membrane properties to exert anticancer effects. Sci Rep. 2016 06 09; 6:27439. PMID: 27278439.
    Citations:    Fields:    Translation:HumansCells
  19. Boareto M, Jolly MK, Goldman A, Pietilä M, Mani SA, Sengupta S, Ben-Jacob E, Levine H, Onuchic JN. Notch-Jagged signalling can give rise to clusters of cells exhibiting a hybrid epithelial/mesenchymal phenotype. J R Soc Interface. 2016 05; 13(118). PMID: 27170649.
    Citations: 12     Fields:    Translation:HumansCells
  20. Kulkarni A, Rao P, Natarajan S, Goldman A, Sabbisetti VS, Khater Y, Korimerla N, Chandrasekar V, Mashelkar RA, Sengupta S. Reporter nanoparticle that monitors its anticancer efficacy in real time. Proc Natl Acad Sci U S A. 2016 Apr 12; 113(15):E2104-13. PMID: 27036008.
    Citations: 5     Fields:    Translation:HumansAnimalsCells
  21. Goldman A. Tailoring combinatorial cancer therapies to target the origins of adaptive resistance. Mol Cell Oncol. 2016 Jan; 3(1):e1030534. PMID: 27308546.
    Citations: 2     
  22. Goldman A, Majumder B, Dhawan A, Ravi S, Goldman D, Kohandel M, Majumder PK, Sengupta S. Temporally sequenced anticancer drugs overcome adaptive resistance by targeting a vulnerable chemotherapy-induced phenotypic transition. Nat Commun. 2015 Feb 11; 6:6139. PMID: 25669750.
    Citations: 39     Fields:    Translation:HumansAnimalsCells
  23. Kulkarni AA, Roy B, Rao PS, Wyant GA, Mahmoud A, Ramachandran M, Sengupta P, Goldman A, Kotamraju VR, Basu S, Mashelkar RA, Ruoslahti E, Dinulescu DM, Sengupta S. Supramolecular nanoparticles that target phosphoinositide-3-kinase overcome insulin resistance and exert pronounced antitumor efficacy. Cancer Res. 2013 Dec 01; 73(23):6987-97. PMID: 24121488.
    Citations: 3     Fields:    Translation:HumansAnimalsCells
  24. Pandey A, Kulkarni A, Roy B, Goldman A, Sarangi S, Sengupta P, Phipps C, Kopparam J, Oh M, Basu S, Kohandel M, Sengupta S. Sequential application of a cytotoxic nanoparticle and a PI3K inhibitor enhances antitumor efficacy. Cancer Res. 2014 Feb 01; 74(3):675-685. PMID: 24121494.
    Citations: 3     Fields:    Translation:HumansAnimalsCells
  25. Triadafilopoulos G, Taddei A, Bechi P, Freschi G, Ringressi MN, Degli'Innocenti DR, Castiglione F, Masini E, Majewski M, Wallner G, Sarosiek J, Dillon JF, McCallum RC, Dvorak K, Goldman A, Woodland P, Sifrim D, Richter JE, Vieth M, Neumann H, Langner C, Ishimura N, Amano Y, Felix VN. Barrett's esophagus: proton pump inhibitors and chemoprevention I. Ann N Y Acad Sci. 2011 Sep; 1232:93-113. PMID: 21950809.
    Citations:    Fields:    Translation:Humans
  26. Richter JE, Penagini R, Tenca A, Pohl D, Dvorak K, Goldman A, Savarino E, Zentilin P, Savarino V, Watson JT, Wong RK, Pace F, Casini V, Peura DA, Herzig SJ, Kamiya T, Pelosini I, Scarpignato C, Armstrong D, DeVault KR, Bechi P, Taddei A, Freschi G, Ringressi MN, Degli'Innocenti DR, Castiglione F, Masini E, Hunt RH. Barrett's esophagus: proton pump inhibitors and chemoprevention II. Ann N Y Acad Sci. 2011 Sep; 1232:114-39. PMID: 21950810.
    Citations: 2     Fields:    Translation:Humans
  27. Dvorak K, Goldman A, Kong J, Lynch JP, Hutchinson L, Houghton JM, Chen H, Chen X, Krishnadath KK, Westra WM. Molecular mechanisms of Barrett's esophagus and adenocarcinoma. Ann N Y Acad Sci. 2011 Sep; 1232:381-91. PMID: 21950830.
    Citations: 8     Fields:    Translation:Humans
  28. Saunders MD, Nieponice A, Dvorak K, Goldman A, Diaz-Cervantes E, De-la-Torre-Bravo A, Sobrino-Cossio S, Torres-Durazo E, Martínez-Carrillo O, Gamboa-Robles J, Upton M, Appelman HD, Bonavina L, Rothstein RI, Velanovich V. Barrett's esophagus: endoscopic treatments I. Ann N Y Acad Sci. 2011 Sep; 1232:140-55. PMID: 21950811.
    Citations:    Fields:    Translation:Humans
  29. Falk GW, Jacobson BC, Riddell RH, Rubenstein JH, El-Zimaity H, Drewes AM, Roark KS, Sontag SJ, Schnell TG, Leya J, Chejfec G, Richter JE, Jenkins G, Goldman A, Dvorak K, Nardone G. Barrett's esophagus: prevalence-incidence and etiology-origins. Ann N Y Acad Sci. 2011 Sep; 1232:1-17. PMID: 21950804.
    Citations: 10     Fields:    Translation:Humans
  30. Shields HM, Nardone G, Zhao J, Wang W, Xing Z, Fang D, Jacobson BC, Romero Y, Dvorak K, Goldman A, Pellegrini CA, Wiley EL, Peura DA, Tatum RP, Schnell TG. Barrett's esophagus: prevalence and incidence of adenocarcinomas. Ann N Y Acad Sci. 2011 Sep; 1232:230-47. PMID: 21950816.
    Citations:    Fields:    Translation:Humans
  31. Goldman A, Chen H, Khan MR, Roesly H, Hill KA, Shahidullah M, Mandal A, Delamere NA, Dvorak K. The Na+/H+ exchanger controls deoxycholic acid-induced apoptosis by a H+-activated, Na+-dependent ionic shift in esophageal cells. PLoS One. 2011; 6(8):e23835. PMID: 21887327.
    Citations: 6     Fields:    Translation:HumansCells
  32. Goldman A, Chen HD, Roesly HB, Hill KA, Tome ME, Dvorak B, Bernstein H, Dvorak K. Characterization of squamous esophageal cells resistant to bile acids at acidic pH: implication for Barrett's esophagus pathogenesis. Am J Physiol Gastrointest Liver Physiol. 2011 Feb; 300(2):G292-302. PMID: 21127259.
    Citations: 13     Fields:    Translation:HumansCells
  33. Goldman A, Shahidullah M, Goldman D, Khailova L, Watts G, Delamere N, Dvorak K. A novel mechanism of acid and bile acid-induced DNA damage involving Na+/H+ exchanger: implication for Barrett's oesophagus. Gut. 2010 Dec; 59(12):1606-16. PMID: 20876775.
    Citations: 10     Fields:    Translation:HumansCells
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact feedbackcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Goldman's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (152)
Explore
_
Co-Authors (14)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.